Conference Coverage
Latest News
What Does Hormone Receptor Mean in BRCA-Associated BC?
Large international study highlights the impact of hormone receptor status in young women with BRCA-associated breast cancer.
Latest News
Black Women With Breast Cancer Face Clinical Inequities
Retrospective analysis finds no clinical trial enrollment, reduced use of targeted treatment, and shortened survival.
Latest News
Twice-Yearly PrEP Gives ‘Huge’ 100% Protection
Twice-yearly injections are 100% effective in preventing new infections, according to the final results from the ...
Latest News
Emergency Contraception Recommended for Teens on Isotretinoin
Types of EC include oral levonorgestrel (plan B), oral ulipristal acetate (ella),...
Latest News
Circulating Tumor DNA Hints at BC Recurrence Risk
Despite suggestive results, researchers say it’s too early to use ctDNA for adjuvant decisions in early, high-risk breast cancer.
Feature
Greater Transparency of Oncologists’ Pharma Relationships Needed
Reducing industry payments to hematologists and oncologists could benefit patients, say experts.
Conference Coverage
Cognitive Decline Minimal After Endocrine + CDK4/6 Inhibition in BC
Authors investigate cognitive functioning in the same cohort used in the SONIA trial and a matched control group of individuals that did not have...
Latest News
Prescribing Epilepsy Meds in Pregnancy: ‘We Can Do Better,’ Experts Say
“There has been almost a 40% decline in the rate of major congenital malformations associated with ASM use in pregnancy, in parallel with a shift...
Conference Coverage
Eribulin Similar to Taxane When Paired With Dual HER2 Blockade in BC
Patients with HER2-positive, locally advanced or metastatic breast cancer who cannot tolerate the standard taxane-based regimen have a new option...
Conference Coverage
PFS Benefits Seen With Palbociclib + Endocrine Therapy in Breast Cancer
Palbociclib plus endocrine therapy or chemotherapy: Which is best in HR+/HER2- metastatic breast cancer?
Feature
New ADC results mixed in metastatic breast cancer
While T-DXd showed promise for yet another indication at ASCO, other findings underscored that much still remains to be learned about this drug...